Ebola Virus Net is the web resource for anyone interested in ebola. Ebola (Ebola hemorrhagic fever), is a severe, often fatal disease in humans and nonhuman primates such as monkeys, gorillas, and chimpanzees. Ebola is a rare and deadly disease caused by infection with a virus of the family Filoviridae, genus Ebolavirus. There are five identified Ebolavirus species, four of which have caused disease in humans. Ebola is found in several African countries. The first Ebola species was discovered in 1976 near the Ebola River in the Democratic Republic of the Congo. Since then, outbreaks have appeared sporadically in Africa. The largest outbreak to date was the epidemic in West Africa, which occurred from December 2013, to January 2016, with 28,646 cases and 11,323 deaths. Other outbreaks in Africa began in the Democratic Republic of the Congo in May 2017 and 2018. In July 2019, the World Health Organization declared the Congo Ebola outbreak a world health emergency.

When an infection does occur in humans, the virus can be spread to others through direct contact with the blood or body fluids of a person who is sick with Ebola, or through contact with objects that have been contaminated with the blood or body fluids of an infected person. Until recent, no vaccines were effective. In December 2016, Ebola was found to be 70–100% prevented by rVSV-ZEBOV vaccine, making it the first proven vaccine against the disease. More than 100,000 people have been vaccinated against Ebola as of 2019.

The objectives of Ebola Virus Net are to be the public and professional information resource for ebola and to serve as a network in the exchange of information and news related to ebola.

• Host Proteins That Impair Ebola Virus Infection Identified by Biomedical Sciences Researchers - Georgia State University News
  Mon, 02 Aug 2021 09:14 GMT
• Remember Ebola: stop mass COVID deaths in Africa - Nature.com
  Tue, 27 Jul 2021 11:09 GMT
• How Contagious Is Ebola? CDC Documents Compare Virus to COVID Delta Variant - Newsweek
  Fri, 30 Jul 2021 09:24 GMT
• Mount Sinai Research Reveals How the Ebola Virus Manages to Evade the Body's Immune Defenses - Mount Sinai
  Tue, 06 Jul 2021 07:00 GMT
• Guinea: Cured Ebola patients from Coyah Ebola Treatment Centre testify - World Health Organization
  Mon, 12 Jul 2021 07:00 GMT
• Mechanisms behind Ebola Virus Spread Revealed Ebola virus, illustration - Genetic Engineering & Biotechnology News
  Thu, 08 Jul 2021 07:00 GMT
• How Ebola virus manages to evade the body's immune defenses - Science Daily
  Wed, 07 Jul 2021 07:00 GMT
• What is Ebola Virus | Detailed information on Ebola Virus - Times of India
  Wed, 21 Jul 2021 12:46 GMT
• Covid-19 has now killed more people in Africa than ebola - NEWS.com.au
  Sun, 01 Aug 2021 08:56 GMT
• Ebola-Like Pig Illness Pops Up in Germany, Doesn't Pose a Threat to Humans - Gizmodo
  Tue, 20 Jul 2021 07:00 GMT
• 'The war has changed': Internal CDC document urges new messaging, warns delta infections likely more severe - The Washington Post
  Fri, 30 Jul 2021 03:58 GMT
• Internal CDC document states delta variant spreads quicker than Ebola, 1918 flu - alreporter.com
  Fri, 30 Jul 2021 20:27 GMT
• C.D.C. Internal Report Calls Delta Variant as Contagious as Chickenpox - The New York Times
  Sun, 01 Aug 2021 07:00 GMT
• This Pandemic Has Turned Our Historical Reaction to Epidemic Disease on Its Head - Esquire.com
  Mon, 02 Aug 2021 13:48 GMT
• UNICEF Guinea Humanitarian Situation Report No1, 01 January - 30 June 2021 - Guinea - ReliefWeb
  Sat, 31 Jul 2021 23:45 GMT

• PRO/AH/EDR> Ebola update (37): research, STAT3 & immune system, lessons, improving response
  Sat, 26 Jun 2021 19:46:55 -0400
  Ebola -- Worldwide/Unknown
  Monash University, Australia, researchers have discovered a key way that one of the world's deadliest pathogens, Ebola virus, evades the immune system. Understanding this process provides new potential targets for the future development of antiviral therapies for a disease that killed over 11 000 people in an outbreak in West Africa between 2014 and 2016, with mortality rates in past outbreaks of 25% to 90%.
  An outbreak of Ebola, for which treatment options are extremely limited, occurred

• Remdesivir for treatment of COVID 19; review of the pharmacological properties, safety and clinical effectiveness Mon, 02 Aug 2021 06:00:00 -0400
  INTRODUCTION: Remdesivir is a nucleoside analog, which inhibits viral RNA replication by blocking RNA-dependent RNA polymerase. First developed and tested during the Ebola epidemic, repurposed, and gained prominence during the Coronavirus disease 19 (COVID 19) pandemic. Based on data from three major trials, remdesivir became the first and only medication to obtain approval from the Food and Drug Administration (FDA) to treat patients hospitalized with COVID 19 disease.
• Proteo-Genomic Analysis Identifies Two Major Sites of Vulnerability on Ebolavirus Glycoprotein for Neutralizing Antibodies in Convalescent Human Plasma Mon, 02 Aug 2021 06:00:00 -0400
  Three clinically relevant ebolaviruses - Ebola (EBOV), Bundibugyo (BDBV), and Sudan (SUDV) viruses, are responsible for severe disease and occasional deadly outbreaks in Africa. The largest Ebola virus disease (EVD) epidemic to date in 2013-2016 in West Africa highlighted the urgent need for countermeasures, leading to the development and FDA approval of the Ebola virus vaccine rVSV-ZEBOV (Ervebo^(®)) in 2020 and two monoclonal antibody (mAb)-based therapeutics (Inmazeb^(®) [atoltivimab,...
• Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention Mon, 02 Aug 2021 06:00:00 -0400
  Different emerging viral infections may emerge in different regions of the world and pose a global pandemic threat with high fatality. Clarification of the immunopathogenesis of different emerging viral infections can provide a plan for the crisis management and prevention of emerging infections. This perspective article describes how an emerging viral infection evolves from microbial mutation, zoonotic and/or vector-borne transmission that progresses to a fatal infection due to overt viremia,...
• Global health security as it pertains to Zika, Ebola, and COVID-19 Mon, 02 Aug 2021 06:00:00 -0400
  PURPOSE OF REVIEW: Due to the impact of the COVID-19 pandemic this past year, we have witnessed a significant acceleration in the science, technology, and policy of global health security. This review highlights important progress made toward the mitigation of Zika, Ebola, and COVID-19 outbreaks. These epidemics and their shared features suggest a unified policy and technology agenda that could broadly improve global health security.
• Deciphering the impact of novel coronavirus pandemic on agricultural sustainability, food security, and socio-economic sectors-a review Sun, 01 Aug 2021 06:00:00 -0400
  The Spanish flu, Asian flu, Hong Kong flu, HIV/AIDS, SARS, Ebola, and Swine flu, among others, have had a significant impact on agriculture, education, the economy, and human activities, including leisureliness, shipping, healthiness, fisheries, mining, industry, and trade. Currently, manhood is dealing with a new epidemic, the infection of the latest coronavirus (2019-nCoV), which causes a deadly disease named COVID-19. This article aims to examine COVID-19's effect on agriculture, education,...
• Computational identification of repurposed drugs against viruses causing epidemics and pandemics via drug-target network analysis Sat, 31 Jul 2021 06:00:00 -0400
  Viral epidemics and pandemics are considered public health emergencies. However, traditional and novel antiviral discovery approaches are unable to mitigate them in a timely manner. Notably, drug repurposing emerged as an alternative strategy to provide antiviral solutions in a timely and cost-effective manner. In the literature, many FDA-approved drugs have been repurposed to inhibit viruses, while a few among them have also entered clinical trials. Using experimental data, we identified...
• Ebola outbreaks: a stress test of the preparedness of medicines regulatory systems for public health crises Sat, 31 Jul 2021 06:00:00 -0400
  In a globalized world, infectious diseases of international concern are inevitable. When they (re-)emerge, the regulatory system works towards mitigating their impact. Ebola outbreaks marked a turning point in regulatory preparedness and efforts led to the accelerated development of therapeutic agents, in a catastrophic environment. However, only one clinical trial determined a vaccine's efficacy. Key lessons were considered and applied thereafter. The collaborative work resulted in the approval...
• Recent developments and strategies of Ebola virus vaccines Fri, 30 Jul 2021 06:00:00 -0400
  The Filovirus family member, Ebola virus (EBOV), is a highly infectious pathogen responsible for viral hemorrhagic fever. EBOV has a fatality rate in the range 50%-90% in primates. The lethal viral hemorrhagic attack in 2014 by EBOV has forced the human race to look for rapid countermeasures. Fortunately, owing to continuous efforts and several vaccine platforms, few potential vaccine candidates are emerging, such as replicative and non-replicative vectored vaccines, polyepitopic or monovalent...
• Religion, Social Connectedness, and Xenophobic Responses to Ebola Thu, 29 Jul 2021 06:00:00 -0400
  This study examined the role of religion in xenophobic responses to the threat of Ebola. Religious communities often offer members strong social ties and social support, which may help members cope with psychological and physical threat, including global threats like Ebola. Our analysis of a nationally representative sample in the U.S. (N = 1,000) found that overall, the more vulnerable to Ebola people felt, the more they exhibited xenophobic responses, but this relationship was moderated by...
• Outcomes of blended learning for capacity strengthening of health professionals in Guinea Thu, 29 Jul 2021 06:00:00 -0400
  CONCLUSION: Two blended courses for capacity strengthening of health professionals were successfully developed and implemented in Guinea.